Version history

{
  "session_id": "sess_sda-2026-04-12-ev-ad-biomarkers_20260412-082939",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"title\": \"NDEV p-tau181 as primary reference standard for early/prodromal AD\",\n      \"mechanism\": \"L1CAM-positive neuron-derived EVs capture pathologically relevant tau181 phosphorylated during early neurodegeneration, enabling plasma-based discrimination of AD from controls.\",\n      \"target_gene\": \"MAPT\",\n      \"confidence_score\": 0.85,\n      \"novelty_score\": 0.50,\n      \"feasibility_score\": 0.55,\n      \"impact_score\": 0.85,\n      \"composite_score\": 0.72,\n      \"testable_prediction\": \"NDEV p-tau181 will discriminate prodromal AD (MCI) from controls with AUC > 0.90 in ≥ 3 independent cohorts.\",\n      \"skeptic_concern\": \"L1CAM capture specificity is confounded by overlapping neural markers; isolation standardization across labs remains unresolved.\"\n    },\n    {\n      \"rank\": 2,\n      \"title\": \"NDEV p-tau231 as upstream ultra-early marker complementary to p-tau181\",\n      \"mechanism\": \"p-tau231 phosphorylation occurs upstream in the tau cascade before fibrillization, reflecting early neuronal tau conformational changes released via exosomal pathways.\",\n      \"target_gene\": \"MAPT\",\n      \"confidence_score\": 0.55,\n      \"novelty_score\": 0.75,\n      \"feasibility_score\": 0.40,\n      \"impact_score\": 0.70,\n      \"composite_score\": 0.62,\n      \"testable_prediction\": \"NDEV p-tau231 will be elevated in preclinical AD cases 12+ months before p-tau181 becomes discriminative.\",\n      \"skeptic_concern\": \"Evidentiary base is substantially weaker than p-tau181; Winston et al. citation incorrectly attributes p-tau181 findings to p-tau231.\"\n    },\n    {\n      \"rank\": 3,\n      \"title\": \"Synaptic protein cargo within NDEVs as functional correlates of early cognitive decline\",\n      \"mechanism\": \"NDEVs containing SNAP25, synaptotagmin, or other synaptic proteins reflect synaptic loss occurring during prodromal AD before volumetric changes.\",\n      \"target_gene\": \"SNAP25/SYT1\",\n      \"confidence_score\": 0.50,\n      \"novelty_score\": 0.70,\n      \"feasibility_score\": 0.45,\n      \"impact_score\": 0.60,\n      \"composite_score\": 0.57,\n      \"testable_prediction\": \"NDEV synaptic protein levels will correlate with CSF synaptic biomarkers (SNAP25, neurogranin) and predict cognitive decline rate in MCI.\",\n      \"skeptic_concern\": \"Synaptic proteins show less AD-specificity than phospho-tau; inflammatory mediator cargo may confound interpretation.\"\n    }\n  ],\n  \"consensus_points\": [\n    \"NDEV-derived phospho-tau species are the most translationally advanced EV biomarkers for early AD\",\n    \"L1CAM-based neuronal EV isolation remains the gold standard approach despite standardization challenges\",\n    \"Technical hurdles (isolation reproducibility, antibody specificity, cross-epitope conflation) are the primary barriers to clinical translation\"\n  ],\n  \"dissent_points\": [\n    \"Whether p-tau231 provides independent diagnostic value beyond p-tau181, or merely reflects less-validated evidence for an upstream mechanism\",\n    \"Whether amyloid-beta or inflammatory mediator EV cargo adds complementary diagnostic value or introduces non-specificity\"\n  ],\n  \"debate_summary\": \"The debate converges on NDEV phospho-tau species as the most viable EV biomarkers, with p-tau181 possessing the strongest evidentiary base (AUC > 0.90) but limited novelty, while p-tau231 offers mechanistic novelty contingent on resolving citation conflation issues. All parties acknowledge that isolation standardization and capture specificity remain the critical technical barriers preventing clinical translation.\"\n}\n```",
  "tokens_used": "893"
}